Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications
A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Healthy Adults.
Journal: Clinical pharmacology in drug development
Published: April 01, 2026
A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P-gp and BCRP Substrates in Healthy Subjects.
Journal: Clinical and translational science
Published: August 21, 2025
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling of Serum M-Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma.
Journal: Clinical and translational science
Published: March 19, 2025
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer.
Journal: Journal of clinical pharmacology
Published: January 24, 2025
Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib.
Journal: Journal of clinical pharmacology
Published: December 20, 2024
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.
Journal: Clinical and translational science
Published: November 15, 2024
Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: November 08, 2024
Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.
Journal: Clinical and translational science
Published: November 08, 2024
Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis.
Journal: Clinical pharmacology and therapeutics
Published: October 21, 2024
A Drug-Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer.
Journal: Clinical pharmacology in drug development
Published: October 04, 2024
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer.
Journal: Journal of clinical pharmacology
Published: October 01, 2024
Moving the needle for oncology dose optimization: A call for action.
Journal: Clinical and translational science
Published: May 31, 2024
Last Updated: 09/26/2026